@dufourjf.bsky.social
A1-antitrypsin aggregate formation in one hepatocyte lead to changes in the metabolic microenvironment inducing stress and proteostatic imbalance in adjacent hepatocytes.
shorturl.at/SlGtl
shorturl.at/SlGtl
Deep Visual Proteomics maps proteotoxicity in a genetic liver disease - Nature
High-resolution spatial proteomics were used to map molecular events during hepatocyte stress in pseudotime across all fibrosis stages, recapitulating known disease progression markers and revealing e...
shorturl.at
April 17, 2025 at 9:28 AM
A1-antitrypsin aggregate formation in one hepatocyte lead to changes in the metabolic microenvironment inducing stress and proteostatic imbalance in adjacent hepatocytes.
shorturl.at/SlGtl
shorturl.at/SlGtl
"burning-out" #MASLD patients with ↓CAP & ↑stiffness have ++ adverse outcomes than patients with stable high CAP/moderate stiffness : ⚠️incidence rates of all-cause mortality, LREs, and decompensation were 7.28, 26.47, and 21.92 per 1000 person-years in "burning-out" patients⚠️ shorturl.at/JOkuF
From
A continuous course of hepatic fat loss with fibrosis progression, referred to as
“burning-out,” was observed in patients with metabolic dysfunction–associated steatotic
liver disease. These patients ...
shorturl.at
April 6, 2025 at 6:08 AM
"burning-out" #MASLD patients with ↓CAP & ↑stiffness have ++ adverse outcomes than patients with stable high CAP/moderate stiffness : ⚠️incidence rates of all-cause mortality, LREs, and decompensation were 7.28, 26.47, and 21.92 per 1000 person-years in "burning-out" patients⚠️ shorturl.at/JOkuF
Reduction of HCC risk with GLP-1RA in diabetics? Comparisons between the GLP-1RA use group (n = 215,970) and the usual care group who continued use of non-GLP-1RA antihyperglycemics (n = 1,203,097), from the VA database. Risk reduction 18%.
shorturl.at/cl2Nc
shorturl.at/cl2Nc
March 13, 2025 at 3:57 PM
Reduction of HCC risk with GLP-1RA in diabetics? Comparisons between the GLP-1RA use group (n = 215,970) and the usual care group who continued use of non-GLP-1RA antihyperglycemics (n = 1,203,097), from the VA database. Risk reduction 18%.
shorturl.at/cl2Nc
shorturl.at/cl2Nc
In compensated MASLD-cirrhosis metabolic surgery reduces the 15 year cumulative incidence of major adverse liver outcomes (MALO) (21% vs 46% without surgery) !⚠️observational study.
shorturl.at/LKnMa
shorturl.at/LKnMa
March 12, 2025 at 4:35 PM
In compensated MASLD-cirrhosis metabolic surgery reduces the 15 year cumulative incidence of major adverse liver outcomes (MALO) (21% vs 46% without surgery) !⚠️observational study.
shorturl.at/LKnMa
shorturl.at/LKnMa
Bookmark your calendar
Not to be missed!
Professor Annalisa Berzigotti, University of Bern, Switzerland
Jean-Pierre Benhamou Clinical State -of-the-Art:
The promise and pitfalls of non-invasive testing
Friday, 9 May, 14:00 - 14:45 CET
Not to be missed!
Professor Annalisa Berzigotti, University of Bern, Switzerland
Jean-Pierre Benhamou Clinical State -of-the-Art:
The promise and pitfalls of non-invasive testing
Friday, 9 May, 14:00 - 14:45 CET
March 11, 2025 at 7:14 AM
Bookmark your calendar
Not to be missed!
Professor Annalisa Berzigotti, University of Bern, Switzerland
Jean-Pierre Benhamou Clinical State -of-the-Art:
The promise and pitfalls of non-invasive testing
Friday, 9 May, 14:00 - 14:45 CET
Not to be missed!
Professor Annalisa Berzigotti, University of Bern, Switzerland
Jean-Pierre Benhamou Clinical State -of-the-Art:
The promise and pitfalls of non-invasive testing
Friday, 9 May, 14:00 - 14:45 CET
Methotrexate hepatotoxicity in rheumatoid arthritis is associated with higher methotrexate-polyglutamates concentrations which are related to eGFR, serum albumin and BMI. shorturl.at/ojBdY
Association of methotrexate polyglutamates concentration with methotrexate efficacy and safety in patients with rheumatoid arthritis treated with predefined dose: results from the MIRACLE trial
The usefulness of methotrexate-polyglutamates (MTX-PGs) concentration for management
of rheumatoid arthritis has been debated. We aimed to clarify the association of MTX-PGs
concentration with efficac...
shorturl.at
March 11, 2025 at 6:46 AM
Methotrexate hepatotoxicity in rheumatoid arthritis is associated with higher methotrexate-polyglutamates concentrations which are related to eGFR, serum albumin and BMI. shorturl.at/ojBdY
HCC Day 2025. Update and controversies in the management of HCC. Top experts. This is free.
cancer-du-foie.ch/en/Events/hc...
cancer-du-foie.ch/en/Events/hc...
February 24, 2025 at 6:58 AM
HCC Day 2025. Update and controversies in the management of HCC. Top experts. This is free.
cancer-du-foie.ch/en/Events/hc...
cancer-du-foie.ch/en/Events/hc...
Prof Kudo explains the results of the LEAP-012 trial which found benefits in combining TACE sessions with lenvatinib and pembrolizumab for unresectable hepatocellular carcinoma
shorturl.at/3RXFv
shorturl.at/3RXFv
LEAP-012 Trial – A New Standard of Care for Unresectable, Non-Metastatic HCC? – Overcome Liver CancerGroup 6Group 6
shorturl.at
February 19, 2025 at 6:59 PM
Prof Kudo explains the results of the LEAP-012 trial which found benefits in combining TACE sessions with lenvatinib and pembrolizumab for unresectable hepatocellular carcinoma
shorturl.at/3RXFv
shorturl.at/3RXFv
There was the recogition of MetALD, now Prof Romeo goes further proposing a liver-centric MASLD and a systemic-MASLD. He explains this in this short video www.youtube.com/watch?v=j-ZE...
Ask the author session with Prof. Stefano Romeo
YouTube video by Swiss Nash Foundation
www.youtube.com
February 12, 2025 at 1:30 PM
There was the recogition of MetALD, now Prof Romeo goes further proposing a liver-centric MASLD and a systemic-MASLD. He explains this in this short video www.youtube.com/watch?v=j-ZE...
Hear and learn from the expert : Treatment of hepatocellular carcinoma with immunotherapy before or after liver resection, adjuvant or neoadjuvant? Don't miss Prof Yopp presentation at the HCC Day 2025. Freburary 27th. Register now this free.
cancer-du-foie.ch/en/Events/hc...
cancer-du-foie.ch/en/Events/hc...
February 11, 2025 at 12:38 PM
Hear and learn from the expert : Treatment of hepatocellular carcinoma with immunotherapy before or after liver resection, adjuvant or neoadjuvant? Don't miss Prof Yopp presentation at the HCC Day 2025. Freburary 27th. Register now this free.
cancer-du-foie.ch/en/Events/hc...
cancer-du-foie.ch/en/Events/hc...
Hear and learn from the expert : Treatment of hepatocellular carcinoma with immunotherapy before and after liver transplantation. Don't miss Prof Coilly presentation with her unique experience at the HCC Day 2025. Freburary 27th. Register now this free.
cancer-du-foie.ch/en/Events/hc...
cancer-du-foie.ch/en/Events/hc...
January 29, 2025 at 7:13 AM
Hear and learn from the expert : Treatment of hepatocellular carcinoma with immunotherapy before and after liver transplantation. Don't miss Prof Coilly presentation with her unique experience at the HCC Day 2025. Freburary 27th. Register now this free.
cancer-du-foie.ch/en/Events/hc...
cancer-du-foie.ch/en/Events/hc...
Reversal of MASH cirrhosis with FGF21 analog: among patients with baseline and week 96 biopsies, 39% of patients treated with 50mg Efruxifermin experienced reversal of cirrhosis compared to 15% for placebo in phase 2b SYMMETRY study. shorturl.at/ZFUSl
shorturl.at
January 28, 2025 at 6:48 AM
Reversal of MASH cirrhosis with FGF21 analog: among patients with baseline and week 96 biopsies, 39% of patients treated with 50mg Efruxifermin experienced reversal of cirrhosis compared to 15% for placebo in phase 2b SYMMETRY study. shorturl.at/ZFUSl
Amycretin, unimolecular dual GLP-1/amylin receptor agonist achieves a 22% weight loss (20 mg qw for 36 wks, phase 1b/2a). shorturl.at/hxpF2
January 27, 2025 at 6:29 AM
Amycretin, unimolecular dual GLP-1/amylin receptor agonist achieves a 22% weight loss (20 mg qw for 36 wks, phase 1b/2a). shorturl.at/hxpF2
Hear and learn from the expert : how to choose and monitor first line immuno-oncology therapy for hepatocellular carcinoma. Don't miss the presentation of Prof Abou-Alfa at the HCC Day 2025. Freburary 27th. Register now this free.
cancer-du-foie.ch/en/Events/hc...
cancer-du-foie.ch/en/Events/hc...
January 24, 2025 at 11:46 AM
Hear and learn from the expert : how to choose and monitor first line immuno-oncology therapy for hepatocellular carcinoma. Don't miss the presentation of Prof Abou-Alfa at the HCC Day 2025. Freburary 27th. Register now this free.
cancer-du-foie.ch/en/Events/hc...
cancer-du-foie.ch/en/Events/hc...
Hear and learn form the expert: How circulating tumor DNA can be leveraged to manage liver cancer. Don't miss the presentaton of Prof JC Nault at the HCC day, February 27th. Register now this is free.
#cancer #liver
cancer-du-foie.ch/en/Events/hc...
#cancer #liver
cancer-du-foie.ch/en/Events/hc...
HCC Day 2025 registration – Overcome Liver CancerGroup 6Group 6
cancer-du-foie.ch
January 21, 2025 at 6:29 AM
Hear and learn form the expert: How circulating tumor DNA can be leveraged to manage liver cancer. Don't miss the presentaton of Prof JC Nault at the HCC day, February 27th. Register now this is free.
#cancer #liver
cancer-du-foie.ch/en/Events/hc...
#cancer #liver
cancer-du-foie.ch/en/Events/hc...
Is obesity a disease or is obesity simply a risk factor for
other illnesses like MASLD ? Call for a better definition of obesity. shorturl.at/Fs3wT
other illnesses like MASLD ? Call for a better definition of obesity. shorturl.at/Fs3wT
January 18, 2025 at 9:05 PM
Is obesity a disease or is obesity simply a risk factor for
other illnesses like MASLD ? Call for a better definition of obesity. shorturl.at/Fs3wT
other illnesses like MASLD ? Call for a better definition of obesity. shorturl.at/Fs3wT
Hear and learn form the expert: How screening for liver cancer in 2025 is changing/improving. Don't miss the presentaton of Prof Singal at the HCC day, February 27th. Register now this is free. #cancer #liver
cancer-du-foie.ch/en/Events/hc...
cancer-du-foie.ch/en/Events/hc...
HCC Day 2025 registration – Overcome Liver CancerGroup 6Group 6
cancer-du-foie.ch
January 17, 2025 at 9:30 AM
Hear and learn form the expert: How screening for liver cancer in 2025 is changing/improving. Don't miss the presentaton of Prof Singal at the HCC day, February 27th. Register now this is free. #cancer #liver
cancer-du-foie.ch/en/Events/hc...
cancer-du-foie.ch/en/Events/hc...
LIver cancer : Inhibiting conjugated BA synthesis boosts tumor-specific T cell responses, reduces tumor growth, and sensitizes tumors to anti–PD-1 immunotherapy. shorturl.at/Qt9rL
Bile acid synthesis impedes tumor-specific T cell responses during liver cancer
The metabolic landscape of cancer greatly influences antitumor immunity, yet it remains unclear how organ-specific metabolites in the tumor microenvironment influence immunosurveillance. We found that...
shorturl.at
January 15, 2025 at 6:27 AM
LIver cancer : Inhibiting conjugated BA synthesis boosts tumor-specific T cell responses, reduces tumor growth, and sensitizes tumors to anti–PD-1 immunotherapy. shorturl.at/Qt9rL
Autologous macrophage therapy for cirrhosis: phase 2 open-label randomized controlled trial: During 360-d follow-up, control group developed 4 liver related events, and 3 deaths (2 liver related), whereas no liver-related severe adverse events or deaths occurred in the treatment group.
January 11, 2025 at 9:45 AM
Autologous macrophage therapy for cirrhosis: phase 2 open-label randomized controlled trial: During 360-d follow-up, control group developed 4 liver related events, and 3 deaths (2 liver related), whereas no liver-related severe adverse events or deaths occurred in the treatment group.
Reposted
New research - TACE combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study
www.thelancet.com/journals/lan...
@thelancet.bsky.social #MedSky #OncSky #LiverSky
www.thelancet.com/journals/lan...
@thelancet.bsky.social #MedSky #OncSky #LiverSky
January 9, 2025 at 8:09 AM
New research - TACE combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study
www.thelancet.com/journals/lan...
@thelancet.bsky.social #MedSky #OncSky #LiverSky
www.thelancet.com/journals/lan...
@thelancet.bsky.social #MedSky #OncSky #LiverSky
More on coffee benefits. Timing. Beginning your day with a coffee rather than finishing your day with a coffee is associated with a reduced mortality risk. shorturl.at/WGErS
January 9, 2025 at 6:31 AM
More on coffee benefits. Timing. Beginning your day with a coffee rather than finishing your day with a coffee is associated with a reduced mortality risk. shorturl.at/WGErS
HCC Day 2025 : Program and registration at cancer-du-foie.ch/en/Events/hc... Bookmark your agenda (27th of February), this is free.
HCC Day 2025 registration – Overcome Liver CancerGroup 6Group 6
cancer-du-foie.ch
January 7, 2025 at 8:15 PM
HCC Day 2025 : Program and registration at cancer-du-foie.ch/en/Events/hc... Bookmark your agenda (27th of February), this is free.
In 2020, 10% of new T2D cases and 3% of new CVD cases worldwide were attributable to sugar-sweetened beverages ! And the liver? shorturl.at/tmjDB
Burdens of type 2 diabetes and cardiovascular disease attributable to sugar-sweetened beverages in 184 countries - Nature Medicine
Estimates from the Global Dietary Database indicated that 2.2 million new type 2 diabetes and 1.2 million new cardiovascular disease cases were attributable to sugar-sweetened beverages worldwide in 2...
shorturl.at
January 7, 2025 at 7:13 AM
In 2020, 10% of new T2D cases and 3% of new CVD cases worldwide were attributable to sugar-sweetened beverages ! And the liver? shorturl.at/tmjDB
In contrast to liver-specific MASLD (blue), cardiometabolic MASLD (red, characterized by dyslipidemia, hypertension, dysglycemia) results in a high risk of incident cardiovascular disease. shorturl.at/ZhFRC
January 6, 2025 at 7:23 AM
In contrast to liver-specific MASLD (blue), cardiometabolic MASLD (red, characterized by dyslipidemia, hypertension, dysglycemia) results in a high risk of incident cardiovascular disease. shorturl.at/ZhFRC
Hepatic TM6SF2 activates antitumour immunity to
suppress MASLD-related HCC shorturl.at/M33WJ
suppress MASLD-related HCC shorturl.at/M33WJ
January 1, 2025 at 6:32 AM
Hepatic TM6SF2 activates antitumour immunity to
suppress MASLD-related HCC shorturl.at/M33WJ
suppress MASLD-related HCC shorturl.at/M33WJ